MRNAModerna, Inc.

Nasdaq modernatx.com


$ 121.15 $ -1.27 (-1.04 %)    

Thursday, 27-Jun-2024 15:59:56 EDT
QQQ $ 482.07 $ 1.24 (0.26 %)
DIA $ 391.62 $ 0.32 (0.08 %)
SPY $ 546.37 $ 0.86 (0.16 %)
TLT $ 93.57 $ 0.37 (0.4 %)
GLD $ 215.08 $ 2.41 (1.13 %)
$ 121.18
$ 121.90
$ 0.00 x 0
$ 0.00 x 0
$ 118.58 - $ 122.11
$ 62.55 - $ 170.47
4,781,106
na
46.29B
$ 0.36
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-02-2024 03-31-2024 10-Q
2 02-23-2024 12-31-2023 10-K
3 11-03-2023 09-30-2023 10-Q
4 08-03-2023 06-30-2023 10-Q
5 05-04-2023 03-31-2023 10-Q
6 02-24-2023 12-31-2022 10-K
7 11-03-2022 09-30-2022 10-Q
8 08-03-2022 06-30-2022 10-Q
9 05-04-2022 03-31-2022 10-Q
10 02-25-2022 12-31-2021 10-K
11 11-04-2021 09-30-2021 10-Q
12 08-05-2021 06-30-2021 10-Q
13 05-06-2021 03-31-2021 10-Q
14 02-26-2021 12-31-2020 10-K
15 10-30-2020 09-30-2020 10-Q
16 08-06-2020 06-30-2020 10-Q
17 05-07-2020 03-31-2020 10-Q
18 02-27-2020 12-31-2019 10-K
19 11-06-2019 09-30-2019 10-Q
20 08-08-2019 06-30-2019 10-Q
21 05-09-2019 03-31-2019 10-Q
22 03-13-2019 12-31-2018 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Development Candidate targets Glypican-3 for the treatment of solid tumors, including hepatocellular carcinomaNomination trigge...

 piper-sandler-reiterates-overweight-on-moderna-maintains-214-price-target

Piper Sandler analyst Edward Tenthoff reiterates Moderna (NASDAQ:MRNA) with a Overweight and maintains $214 price target.

 evercore-isi-group-maintains-in-line-on-moderna-maintains-120-price-target

Evercore ISI Group analyst Cory Kasimov maintains Moderna (NASDAQ:MRNA) with a In-Line and maintains $120 price target.

 cdc-advisor-panel-recommends-rsv-shots-in-us-for-people-above-75-years-analyst-says-decision-negative-for-gsk

The CDC's ACIP recommends RSV vaccines for adults 75+, and for those 60-74 with chronic conditions. GSK's Arexvy is app...

Core News & Articles

- Reuters

Core News & Articles

- Reuters

 why-is-moderna-stock-trading-lower-on-wednesday

The CDC's Advisory Committee on Immunization Practices is set to discuss recommendations for RSV, influenza, and COVID-19 v...

 beating-cancer-is-still-an-everything-but-easy-challenge-that-pharmaceutical-companies-cannot-solve-overnight

On Tuesday, Merck Group revealed an unexpected decision to end a Phase III trial of its cancer drug Xevinapant. This move threa...

 whats-going-on-with-eli-lilly-stock-on-tuesday

Eli Lilly collaborates with Microsoft-backed OpenAI to leverage generative AI for developing novel antimicrobials targeting dru...

 covid-19-pharma-stars-continue-their-quest-to-set-new-standards-in-cancer-treatment

AstraZeneca PLC (NASDAQ: AZN) kicked off the week by receiving approval from the U.S. Food and Drug Administration for its bloc...

 openai-and-color-health-develop-ai-driven-cancer-care-solutions-report

OpenAI and startup Color Health have developed an AI assistant, named 'copilot', to support physicians in creating pers...

Core News & Articles

- Reuters

 moderna-says-higher-efficacy-was-observed-in-mrna-1283-compared-to-spikevax-in-adults-18-years-of-age-and-older

"We are very pleased that mRNA-1283 has now met its primary vaccine efficacy endpoint in Phase 3, and showed higher efficac...